The Anti-Fib Wrote:
-------------------------------------------------------
> That is what I meant to say, only way to know for
> sure that Atrial stunning is not occuring is via
> getting a TEE. I meant to imply that their was
> uncertainty or the possibility of stunning, I
> never meant to imply that Atrial Stunning would
> always occur for days.
>
> Anticoagulation is given not just to deal with
> exsisting clots, but to prevent potential clots
> and their is always uncertainty whether or not a
> clot may form. Stunning occurs because of the
> Atria muscles have been fibrillating (contracting
> at 400-600 beats per minute), so they are
> "stunned" and don't contract properly, not because
> of a Electrocardioversion.
>
> Why do you think a little Alivecor device, your
> ears, or your senses can tell you if your LAA is
> contracting properly?
>
> The original question posed was about
> Anti-Coagulation and Guidelines that took into
> account the frequency of episodes, and in Lynn's
> case 52 episodes a year is very frequent. I tried
> to explain why the more frequent that the episodes
> are, that it would change the argument in favor of
> Anticoagulation.
>
> Go ask your Doctor about 50+ episodes a year, and
> see what they say.
Anti-AFIB,
Its certainly true that the more frequent the episodes and the longer term the duration of those episodes the greater the logic and pressure to add anti-coagulation to the equation, all else being equal. Though for those with a low risk CHADS2 score and no other obvious risk factors beyond just the AFIB that threshold for adding in OAC is considerable higher than for those with even one extra risk factor, depending on what it is.
And you are very right too that OAC drugs are not just given to deal with existing clots as their main function is to prevent those clots from forming to begin with as you noted Anti-AFIB.
Your comment above about using one's ears, senses or an AliveCor to detect if the LAA is contracting properly ... I think you must have meant to say the left ventricle and to a degree the left atrium on EKG? The LAA mechanical function is really only detected with accuracy via TEE or angiography. Also Cardiac MRI or CT can detect some info about real time LAA mechanical function, but is not typically used for such due to cost and inconvenience.
I know of no clear way to define just what the LAA itself is reliably doing via a stethoscope, finger palpation or an Alivecor.
If you are looking at absolute risk/benefit statistic rather then the relative risk picture so often used to justify a give drug or therapy, it still is a bit of a stretch to recommend anticoagulation to a mild to moderate paroxysmal afibbers who has no other cardiovascular co-morbidities unless they have very frequent longer duration episodes.
More and more evidence points to the combination of the impact of a quivering atria during AFIB along with added risk factors for cardiovascular dysfunction that is what adds the real weight behind the anti-coagulation argument rather than just relatively short term paroxysmal episodes in a person with little to no added cardiovascular risk factors in play.
Its true that many docs will readily agree to put a patient on OACs a little earlier than the guidelines strictly spell out, and would rather err that way than risk their patient perhaps being an odd ball that had a stroke on their watch anyway even in spite of otherwise very good health and a CHADS2 of less than 1 and no other real risks factors that jump out. That doesn't make it necessary the better medical decision but you have litigious considerations and those other kinds of factors that weigh in on the decision too often times beyond the strict medical science as best we know it.
Nevertheless, I agree, as a person's AFIB burden begins to increase toward persistence and certainly when it has crossed that line, even if they were so called vagal lone afibbers up until the increase in burden, I would also strongly recommend adopting pharmaceutical coagulation at that point.
The exact timing of adopting OAC, as you noted, is not a black and white line, and should be the result of a collective decision between hopefully an informed patient and an even more informed physician (at least one would hope)
I would be far more likely to accept a recommendation for OAC if I were a paroxysmal patient with one or more additional CVD risk factors in addition to my AFIB, even with less frequent episodes and a bit total AFIB burden, than I would be for a purely paroxysmal afibber with no such added risks at all even with somewhat more frequent episodes and a bit more total AFIB burden.
Such are the nuances we face in making a wise decision while keeping in mind that these drugs are not a panacea, nor are they as risk free as they are sometimes painted. Especially when the more real world absolute risk/benefit equation is applied to the many studies looking at this question and not just the relative risk prism thorough which the risks of a stroke can look far worse and benefits of the drug significantly better than they really are for a given patient to truly benefit out of a large number of others who also need to take the drug who will derive no benefit and some added risks.
When looking at some of these large studies and adjusting warfarin to include a consistently maintained and verified INR to get a better comparison with Eliquis and Xeralto, those absolute risks are somewhere in the range of around 100 total people needing to be treated (NNT) for just a few who actually benefit from the treatment over time.
The relative risk analysis, for example, might imply a 30% to 50% effect window while the absolute risks in the form of NNT ( numbered needed to treat) with this class of drugs when looking at the very same data, can be in the 1% to 5% range for those who actually benefit from taking the drug out of the whole study cohort, depending on the nature of the study.
To my knowledge, Anti-Afib, there is no hard and fast rule that a clot in the LAA from an AFIB episode will automatically be broken down and lysed within the bloodstream in 20 days. Its much more variable than that and some can last a good deal longer and some break down in much shorter time frame. It depends on a large number of variables including how well the natural clot busing enzymes in a given body are working, the size and density of the clot, the velocity of blood flow at the point in the LAA or LA that the clot is located ... for example a large clot lodged deep within the nooks and cranny's of striated pectinate muscles that form a labyrinth-like cave in the back half of many LAA morphologies, can last a very long time before breakdown or before breaking loose and gaining access to the venous blood flow and causing a stroke or PE at any time even much later than the conversion point to NSR and well after a cardioversion as well at times ... and a number of other factors.
Typically, when a clot is found that is a serious threat, heparin is started and/or an OAC perhaps with an anti-platelet drug are used depending on the given case.
The earliest a clot has been seen to form during an AFIB episode is 5 hours after onset of the episode, though more commonly it is a good eal later than 24 to 48 hours. Hence the general 48 hour rule.
It obvious you have done a lot of investigation and inquiry on these issue and I applaud that and some of your points in this thread Anti-Afib are well taken and address some valid concerns, but the info you have received also seems to paint the risks, and thus need, for OAC as being more urgent than the guidelines and real world scenarios portray, especially for those paroxysmal afibbers with little to no cardiovascular co-morbidites.
Its all good and stimulates a good discussion we can all learn from and thanks sharing your thoughts on this important issue.
Shannon